1st Quarter - Amendment

ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY

Firm
Client
Income
—
Expenses
$66,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 22, 2009 $135,478 Replaced
1st Quarter - Amendment (this page) Aug 6, 2009 $66,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Labor Issues/Antitrust/Workplace LBR

Legislation granting independent pharmacists collective bargaining rights.

LobbyistCovered position, as disclosed
MELISSA ANDEL —
RYAN DAY —
LAUREN LEA FULLER Chief Investigative Counsel, Sen. Finance Cmte.
WILLIAM HERMELIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Proposed changes to the Medicare Part D prescripion drug benefit. Adjustments to Medicaid prescription drug reimbursement rates.

LobbyistCovered position, as disclosed
MELISSA ANDEL —
RYAN DAY —
LAUREN LEA FULLER Chief Investigative Counsel, Sen. Finance Cmte.
WILLIAM HERMELIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Establishing a regulatory pathway for FDA approval of follow-on biologics products; electronic prescribing of controlled substances and generally; regulation of online pharmacies; importation of prescription drugs; federal funding for academic detailing programs; promotion of the use of generic drugs; federal funding for comparative effectiveness research

LobbyistCovered position, as disclosed
MELISSA ANDEL —
RYAN DAY —
LAUREN LEA FULLER Chief Investigative Counsel, Sen. Finance Cmte.
WILLIAM HERMELIN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Increased federal funding for comparative effectiveness research, establishment of a public-private entity to coordinate comparative effectiveness research, legislation relating to health information technology and elecronic prescribing; the professional role of pharmacists in health care reform

LobbyistCovered position, as disclosed
MELISSA ANDEL —
RYAN DAY —
LAUREN LEA FULLER Chief Investigative Counsel, Sen. Finance Cmte.
WILLIAM HERMELIN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.